Authors
Dilara Denizmen Zorba, Yasemin Sanli
Published in
Magnetic resonance imaging clinics of North America. Volume 35. Issue 1. Pages 177-188. Epub Oct 23, 2026.
Abstract
Prostate-specific membrane antigen (PSMA)-targeted theranostics have become an important component of advanced prostate cancer management by integrating molecular imaging with radioligand therapy. This review summarizes the biologic rationale for PSMA targeting, the role of PSMA PET in patient selection, and the clinical evidence supporting PSMA-directed radioligand therapy. Practical aspects of treatment administration, toxicity monitoring, response assessment, and sequencing are discussed, together with emerging strategies involving novel ligands, alpha emitters, dosimetry, and combination approaches.
PMID:
43039498
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0